Hemogenyx Pharmaceuticals (LSE:HEMO) EBIT : £-4.89 Mil (TTM As of Jun. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Hemogenyx Pharmaceuticals EBIT?

Hemogenyx Pharmaceuticals's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2024 was £-2.67 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was £-4.89 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Hemogenyx Pharmaceuticals's annualized ROC % for the quarter that ended in Jun. 2024 was -123.44%. Hemogenyx Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -144.89%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Hemogenyx Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -30.85%.

Hemogenyx Pharmaceuticals EBIT Historical Data

The historical data trend for Hemogenyx Pharmaceuticals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hemogenyx Pharmaceuticals EBIT Chart

Hemogenyx Pharmaceuticals Annual Data

Trend

Feb15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-1.46

-2.06

-2.51

-3.99

-6.38

Hemogenyx Pharmaceuticals Semi-Annual Data
	Feb15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
EBIT	Get a 7-Day Free Trial													-1.14	-2.85	-4.16	-2.22	-2.67

Competitive Comparison of Hemogenyx Pharmaceuticals's EBIT

For the Biotechnology subindustry, Hemogenyx Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hemogenyx Pharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemogenyx Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Hemogenyx Pharmaceuticals's EV-to-EBIT falls into.

Hemogenyx Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-4.89 Mil.

Hemogenyx Pharmaceuticals (LSE:HEMO) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Hemogenyx Pharmaceuticals's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

	ROC % (Q: Jun. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Jun. 2024 ))	/ count )
=	-5.382 * ( 1 - 0% )	/	( (4.556	+	4.164)	/ 2 )
=	-5.382	/	4.36
=	-123.44 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	6.106	-	0.302	-	( 1.248	-	max(0, 0.652	-	2.17	+	1.248	))
=	4.556

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	6.116	-	0.309	-	( 1.643	-	max(0, 0.564	-	2.471	+	1.643	))
=	4.164

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Hemogenyx Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Jun. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-5.348	/	( ( (3.312 + max(0.543, 0))	+	(3.007 + max(0.52, 0)) )	/	2 )
=	-5.348	/	( ( 3.855	+	3.527 )	/	2 )
=	-5.348	/	3.691
=	-144.89 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.001	+	0	+	0.921)	-	(0.302	+	0	+	0.077)
=	0.543

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.828	+	0	+	0)	-	(0.309	+	0	+	-0.001)
=	0.52

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Hemogenyx Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2024 )
	=	-4.893	/	15.860
	=	-30.85 %

Hemogenyx Pharmaceuticals EBIT Related Terms

Thank you for viewing the detailed overview of Hemogenyx Pharmaceuticals's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Hemogenyx Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemogenyx Pharmaceuticals PLC (LSE:HEMO) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

60 Gracechurch Street, 6th Floor, London, GBR, EC3V 0HR

Website

https://www.hemogenyx.com

Hemogenyx Pharmaceuticals PLC is an operator of a biotechnology company intended to focus on the discovery, development, and commercialization of novel therapies and treatments for blood diseases, like leukaemia and lymphoma. The company's technologies aim to change the way in which bone marrow/hematopoietic stem cell transplants are performed and improve their efficacy, its three distinct products include an immunotherapy product for the treatment of relapsed/refractory acute myeloid leukaemia (AML) and patient conditioning, the bi-specific antibody, for the treatment of AML and a community-based rehabilitation/Biomedical engineering platform, enabling users to generate treatments for existing and emerging viral infections.

Hemogenyx Pharmaceuticals Headlines

No Headlines